Drug intelligence / Profile preview

Trineumin

Development stage: Phase 2
Lead developer: PRG Science & Technology
Modality: Small Molecules

Overview

Trineumin is a synthetic small molecule drug initially developed by PRG S&T Co., Ltd. It has received orphan drug designation in the United States for the treatment of neurofibromatosis type 2 and is currently in Phase 1 clinical trials for this indication. The compound’s chemical name is 4-(4-(2-(Diethylamino)ethoxy)phenyl)-1-(4-methoxybenzyl)-1H-1,2,3-triazol-5-amine. Its mechanism of action and specific targets have not been fully disclosed in public sources as of now.

Other names: 4-(4-(2-(Diethylamino)ethoxy)phenyl)-1-(4-methoxybenzyl)-1H-1,2,3-triazol-5-amine

Beyond the preview

Go deeper on Trineumin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trineumin.

Explore the full profile